TL;DR
This review explores the intricate network of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in clear cell renal cell carcinoma (ccRCC), highlighting their crucial roles in tumor progression and the tumor microenvironment (TME). Understanding these interactions is vital for developing novel diagnostic biomarkers and therapeutic strategies for this aggressive cancer.
What Problem Does This Paper Address?
Clear cell renal cell carcinoma (ccRCC) is a deadly cancer with increasing incidence and mortality, yet current treatments for advanced or metastatic cases remain largely ineffective, leading to poor patient prognoses. A major contributing factor to this challenge is the complex and heterogeneous tumor microenvironment (TME). While non-coding RNAs, specifically lncRNAs and miRNAs, are known to play significant roles in various cancers, their precise involvement in ccRCC, particularly in shaping the TME, is not fully understood. This paper aims to bridge this knowledge gap by reviewing the current understanding of the lncRNA/miRNA/mRNA axis in ccRCC pathogenesis, its influence on the TME, and its potential as a therapeutic target.
Methods
This paper is a comprehensive review, synthesizing existing research rather than presenting new experimental data. The authors have systematically analyzed and compiled findings from numerous studies to provide a holistic overview of the lncRNA/miRNA/mRNA axis in ccRCC. The review categorizes the regulatory mechanisms of lncRNA-miRNA interactions, discusses the biological roles of these axes in tumor promotion and inhibition, explores their significance in drug resistance, and examines their impact on various components of the TME (immune cells, non-immune cells, extracellular matrix, and signaling molecules).
Datasets
Not discussed in the paper. This is a review article that synthesizes existing literature.
Key Insights and Ideas
- Complex Regulatory Networks: The lncRNA/miRNA/mRNA axis forms a sophisticated regulatory network where lncRNAs can act as "sponges" for miRNAs, influencing miRNA availability and thus the expression of target mRNAs. This intricate interplay is central to ccRCC development.
- Dual Role of lncRNAs: LncRNAs can either promote or inhibit tumor progression in ccRCC, depending on their specific interactions with miRNAs and their downstream targets. This highlights the context-dependent nature of their function.
- TME as a Critical Player: The tumor microenvironment is not just a passive bystander but an active participant in ccRCC progression. LncRNA/miRNA networks significantly influence immune cells, non-immune cells, the extracellular matrix, and signaling molecules within the TME, impacting tumor growth, metastasis, and immune evasion.
- Therapeutic and Diagnostic Potential: The stability of lncRNAs and miRNAs in biological fluids (serum, urine) makes them promising candidates for non-invasive diagnostic and prognostic biomarkers. Furthermore, targeting these regulatory axes offers a novel therapeutic avenue for overcoming drug resistance and improving treatment efficacy.
Key Results
The review details numerous specific lncRNAs and miRNAs and their associated mRNA targets that are implicated in ccRCC progression. For instance:
- Promoting Progression: LncRNAs like PVT1, MALAT1, and TUG1 are frequently upregulated and promote cell proliferation, migration, and invasion by sponging specific miRNAs (e.g., PVT1 sponges miR-328-3p, MALAT1 sponges miR-200s).
- Inhibiting Progression: Conversely, lncRNAs such as LET and TCL6 are often downregulated and act as tumor suppressors by interacting with oncogenic miRNAs.
- Biomarker Potential: Several lncRNAs (e.g., GIHCG, OTUD6B-AS1) and miRNAs (e.g., miR-210, miR-378) have demonstrated significant diagnostic and prognostic value in ccRCC tissues and serum, with high sensitivity and specificity reported in various studies.
- Drug Resistance: The lncRNA/miRNA/mRNA axis plays a critical role in resistance to targeted therapies like sunitinib. For example, lncRNA ARSR enhances sunitinib resistance by sponging miR-34 and miR-449.
Limitations and Future Work
The authors acknowledge that while the role of the lncRNA/miRNA/mRNA axis in promoting or inhibiting ccRCC progression is increasingly understood, its specific role in regulating the crosstalk between ccRCC cells and the TME requires further clarification. Additionally, the clinical application of these axes, particularly in terms of drug delivery and therapeutic strategies, is still in its early stages.
Future research should focus on:
- Delivery Mechanisms: Developing effective methods for delivering lncRNAs or miRNAs to ccRCC cells to enhance therapeutic efficacy.
- Immune Escape Modulation: Investigating how these axes can be targeted to overcome immune escape in ccRCC.
- Pharmacokinetics: Evaluating the doses and pharmacokinetic profiles of lncRNA-based therapies.
- TME Interactions: Further elucidating the intricate interactions between the lncRNA/miRNA/mRNA axis and various TME components.
Ultimately, continued research in this area is crucial for gaining deeper insights into ccRCC pathogenesis and for developing novel diagnostic and therapeutic strategies.
Summary updated